[144] Insmed, Inc. SEC Filing
Form 144 filed for Insmed, Inc. (INSM) reports a proposed sale of 10,000 shares of common stock through Merrill Lynch in Orlando, to be executed on or about 08/12/2025 on NASDAQ with an aggregate market value of $1,215,350. The filing lists total shares outstanding of 211,374,786, which makes the proposed block a very small fraction of the company's capitalization.
The securities to be sold were acquired via stock option transactions reported on 05/18/2018 (6,702 shares) and 05/16/2019 (6,066 shares). Several identifying fields in the filing appear blank or unspecified, and the form includes the standard representation that the seller does not possess undisclosed material adverse information.
Il modulo 144 depositato per Insmed, Inc. (INSM) segnala una proposta di vendita di 10.000 azioni ordinarie tramite Merrill Lynch a Orlando, da eseguirsi in data o intorno al 12/08/2025 sul NASDAQ, per un valore di mercato complessivo di $1.215.350. La comunicazione indica un totale di azioni in circolazione pari a 211.374.786, pertanto il blocco proposto rappresenta una quota molto ridotta della capitalizzazione della societ脿.
I titoli da vendere sono stati acquisiti mediante transazioni di opzioni su azioni riportate il 18/05/2018 (6.702 azioni) e il 16/05/2019 (6.066 azioni). Diversi campi identificativi nella dichiarazione risultano vuoti o non specificati, e il modulo riporta la consueta dichiarazione secondo cui il venditore non 猫 in possesso di informazioni materiali sfavorevoli non divulgate.
El formulario 144 presentado para Insmed, Inc. (INSM) informa una propuesta de venta de 10.000 acciones ordinarias a trav茅s de Merrill Lynch en Orlando, que se ejecutar铆a en o alrededor del 08/12/2025 en NASDAQ, con un valor de mercado agregado de $1.215.350. La presentaci贸n indica un total de acciones en circulaci贸n de 211.374.786, por lo que el bloque propuesto constituye una fracci贸n muy peque帽a de la capitalizaci贸n de la compa帽铆a.
Los valores a vender se adquirieron mediante transacciones de opciones sobre acciones registradas el 18/05/2018 (6.702 acciones) y el 16/05/2019 (6.066 acciones). Varios campos identificativos en la presentaci贸n aparecen en blanco o sin especificar, y el formulario incluye la declaraci贸n est谩ndar de que el vendedor no posee informaci贸n adversa material no divulgada.
Insmed, Inc. (INSM)鞐� 雽�頃� 鞝滌稖霅� Form 144電� Merrill Lynch(鞓灉霃�)毳� 韱淀暣 氤错喌欤� 10,000欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃橁碃 鞛堨溂氅�, 頃措嫻 瓯半灅電� 2025/08/12 瓴�(霕愲姅 攴� 氍措牭) NASDAQ鞐愳劀 鞁ろ枆霅� 鞓堨爼鞚搓碃 齑� 鞁滉皜臧� $1,215,350鞛呺媹雼�. 鞝滌稖靹滊鞐愲姅 齑� 氚滍枆欤检嫕靾橁皜 211,374,786欤茧 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 毵る弰 氍茧焿鞚� 須岇偓 鞛愲掣鞚� 毵れ毎 鞛戩潃 攵�攵勳潉 彀頃╇媹雼�.
毵る弰霅� 歃濌秾鞚� 2018/05/18鞐� 氤搓碃霅� 鞀ろ啞鞓奠厴 瓯半灅搿� 旆摑頃� 6,702欤检檧 2019/05/16鞐� 氤搓碃霅� 6,066欤检瀰雼堧嫟. 鞝滌稖靹滊鞚� 鞐煬 鞁濍硠 頃鞚� 牍勳柎 鞛堦卑雮� 氙戈赴鞛悩鞏� 氤挫澊氅�, 靹滌嫕鞐愲姅 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Le formulaire 144 d茅pos茅 pour Insmed, Inc. (INSM) signale une proposition de vente de 10 000 actions ordinaires via Merrill Lynch 脿 Orlando, 脿 ex茅cuter aux alentours du 12/08/2025 sur le NASDAQ, pour une valeur de march茅 totale de 1 215 350 $. Le d茅p么t indique un total de 211 374 786 actions en circulation, ce qui fait que le lot propos茅 repr茅sente une fraction tr猫s faible de la capitalisation de la soci茅t茅.
Les titres 脿 vendre ont 茅t茅 acquis par des op茅rations d'options sur actions d茅clar茅es le 18/05/2018 (6 702 actions) et le 16/05/2019 (6 066 actions). Plusieurs champs d'identification dans la d茅claration semblent vides ou non sp茅cifi茅s, et le formulaire comporte la mention standard selon laquelle le vendeur ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Das f眉r Insmed, Inc. (INSM) eingereichte Formular 144 meldet einen geplanten Verkauf von 10.000 Stammaktien 眉ber Merrill Lynch in Orlando, der am oder um den 12.08.2025 an der NASDAQ ausgef眉hrt werden soll, mit einem aggregierten Marktwert von $1.215.350. In der Einreichung sind insgesamt 211.374.786 ausstehende Aktien angegeben, wodurch das vorgeschlagene Paket einen sehr kleinen Bruchteil der Marktkapitalisierung des Unternehmens darstellt.
Die zu ver盲u脽ernden Wertpapiere wurden durch Aktienoptionsgesch盲fte erworben, die am 18.05.2018 (6.702 Aktien) und am 16.05.2019 (6.066 Aktien) gemeldet wurden. Mehrere Identifikationsfelder in der Einreichung erscheinen leer oder nicht angegeben, und das Formular enth盲lt die 眉bliche Erkl盲rung, dass der Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.
- None.
- Seller identity not specified in the visible filing fields, reducing transparency about who is proposing the sale.
- Filer contact/CIK and signature/date fields are not provided in the content supplied, limiting verifiability of the notice.
Insights
TL;DR: Proposed sale of 10,000 INSM shares (~0.0047% of outstanding) valued at $1.215M鈥攊mmaterial to overall capitalization.
The filing shows a small disposition relative to 211,374,786 shares outstanding: 10,000/211,374,786 equals approximately 0.0047% of the float implied by outstanding shares. The broker is listed as Merrill Lynch (Orlando). The reported acquisition lots (6,702 shares from 05/18/2018 and 6,066 shares from 05/16/2019) indicate the seller holds option-derived lots larger than the proposed sale, but the filing does not identify the named seller in the provided fields. From an investor-impact perspective, the size and timing (08/12/2025) make market impact negligible.
TL;DR: Routine Rule 144 notice filed but several identification fields are missing, which reduces transparency for market participants.
The form contains the required Rule 144 representation about absence of undisclosed material adverse information and documents the broker and sale details. However, key identifying fields (the filer CIK/contact info and the "Name of Person for Whose Account" appear blank in the provided content), and signature/date entries are not shown. That limits the utility of the filing for due diligence and public record verification, though it does not alter the factual details of the proposed transaction as reported.
Il modulo 144 depositato per Insmed, Inc. (INSM) segnala una proposta di vendita di 10.000 azioni ordinarie tramite Merrill Lynch a Orlando, da eseguirsi in data o intorno al 12/08/2025 sul NASDAQ, per un valore di mercato complessivo di $1.215.350. La comunicazione indica un totale di azioni in circolazione pari a 211.374.786, pertanto il blocco proposto rappresenta una quota molto ridotta della capitalizzazione della societ脿.
I titoli da vendere sono stati acquisiti mediante transazioni di opzioni su azioni riportate il 18/05/2018 (6.702 azioni) e il 16/05/2019 (6.066 azioni). Diversi campi identificativi nella dichiarazione risultano vuoti o non specificati, e il modulo riporta la consueta dichiarazione secondo cui il venditore non 猫 in possesso di informazioni materiali sfavorevoli non divulgate.
El formulario 144 presentado para Insmed, Inc. (INSM) informa una propuesta de venta de 10.000 acciones ordinarias a trav茅s de Merrill Lynch en Orlando, que se ejecutar铆a en o alrededor del 08/12/2025 en NASDAQ, con un valor de mercado agregado de $1.215.350. La presentaci贸n indica un total de acciones en circulaci贸n de 211.374.786, por lo que el bloque propuesto constituye una fracci贸n muy peque帽a de la capitalizaci贸n de la compa帽铆a.
Los valores a vender se adquirieron mediante transacciones de opciones sobre acciones registradas el 18/05/2018 (6.702 acciones) y el 16/05/2019 (6.066 acciones). Varios campos identificativos en la presentaci贸n aparecen en blanco o sin especificar, y el formulario incluye la declaraci贸n est谩ndar de que el vendedor no posee informaci贸n adversa material no divulgada.
Insmed, Inc. (INSM)鞐� 雽�頃� 鞝滌稖霅� Form 144電� Merrill Lynch(鞓灉霃�)毳� 韱淀暣 氤错喌欤� 10,000欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃橁碃 鞛堨溂氅�, 頃措嫻 瓯半灅電� 2025/08/12 瓴�(霕愲姅 攴� 氍措牭) NASDAQ鞐愳劀 鞁ろ枆霅� 鞓堨爼鞚搓碃 齑� 鞁滉皜臧� $1,215,350鞛呺媹雼�. 鞝滌稖靹滊鞐愲姅 齑� 氚滍枆欤检嫕靾橁皜 211,374,786欤茧 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 毵る弰 氍茧焿鞚� 須岇偓 鞛愲掣鞚� 毵れ毎 鞛戩潃 攵�攵勳潉 彀頃╇媹雼�.
毵る弰霅� 歃濌秾鞚� 2018/05/18鞐� 氤搓碃霅� 鞀ろ啞鞓奠厴 瓯半灅搿� 旆摑頃� 6,702欤检檧 2019/05/16鞐� 氤搓碃霅� 6,066欤检瀰雼堧嫟. 鞝滌稖靹滊鞚� 鞐煬 鞁濍硠 頃鞚� 牍勳柎 鞛堦卑雮� 氙戈赴鞛悩鞏� 氤挫澊氅�, 靹滌嫕鞐愲姅 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Le formulaire 144 d茅pos茅 pour Insmed, Inc. (INSM) signale une proposition de vente de 10 000 actions ordinaires via Merrill Lynch 脿 Orlando, 脿 ex茅cuter aux alentours du 12/08/2025 sur le NASDAQ, pour une valeur de march茅 totale de 1 215 350 $. Le d茅p么t indique un total de 211 374 786 actions en circulation, ce qui fait que le lot propos茅 repr茅sente une fraction tr猫s faible de la capitalisation de la soci茅t茅.
Les titres 脿 vendre ont 茅t茅 acquis par des op茅rations d'options sur actions d茅clar茅es le 18/05/2018 (6 702 actions) et le 16/05/2019 (6 066 actions). Plusieurs champs d'identification dans la d茅claration semblent vides ou non sp茅cifi茅s, et le formulaire comporte la mention standard selon laquelle le vendeur ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Das f眉r Insmed, Inc. (INSM) eingereichte Formular 144 meldet einen geplanten Verkauf von 10.000 Stammaktien 眉ber Merrill Lynch in Orlando, der am oder um den 12.08.2025 an der NASDAQ ausgef眉hrt werden soll, mit einem aggregierten Marktwert von $1.215.350. In der Einreichung sind insgesamt 211.374.786 ausstehende Aktien angegeben, wodurch das vorgeschlagene Paket einen sehr kleinen Bruchteil der Marktkapitalisierung des Unternehmens darstellt.
Die zu ver盲u脽ernden Wertpapiere wurden durch Aktienoptionsgesch盲fte erworben, die am 18.05.2018 (6.702 Aktien) und am 16.05.2019 (6.066 Aktien) gemeldet wurden. Mehrere Identifikationsfelder in der Einreichung erscheinen leer oder nicht angegeben, und das Formular enth盲lt die 眉bliche Erkl盲rung, dass der Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen besitzt.
FAQ
What does the INSM Form 144 disclose?
How large is the 10,000-share block relative to Insmed's outstanding shares?
Who is the broker handling the proposed sale in the INSM Form 144?
When were the securities proposed for sale originally acquired?
Does the filing state whether the seller possesses undisclosed material information?
